Business
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
PARIS, February 18, 2026--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the strategic expansion of its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones.
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/49d66a81528658f2ac330104582d83f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t9A0xVs5aeEbxAxHklpYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/49d66a81528658f2ac330104582d83f2","width":480,"height":204}},"lazy":false},{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}},{"type":"text","content":"PARIS, February 18, 2026--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the strategic expansion of its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones.","length":460,"tagName":"p"},{"type":"text","content":"The company named Fang Li, Ph.D., RAC, as Chief Regulatory Affairs & Quality Officer, and Sabrina Chekroun, Pharm.D., as Senior Vice President, Regulatory Affairs and Quality. Sabrina Chekroun will report to Fang Li. Fang Li is based in the U.S., and Sabrina Chekroun is based in France. The appointments came as GenSight progressed in its early access program with individual patient authorizations in France and Israel and an individual IND approval in the United States. These appointments will support the company’s global regulatory strategy.","length":551,"tagName":"p"},{"type":"text","content":""We are excited to welcome Fang and Sabrina to the team as we enter a pivotal growth phase this year," said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "On behalf of the GenSight team, I take this opportunity to express our deepest gratitude to Magali Gibou, whose leadership, insights, and collegial support played an indispensable role in GenSight’s consolidation and transformation over the past two years."","length":453,"tagName":"p"},{"type":"text","content":""As we prepare for a year of advances, m...